Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough

Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough

Bibliographic Details
Main Authors: David Muccino, George Philip, A.H. Morice, S.S. Birring, L. Mcgarvey, P.V. Dicpinigaitis, I.D. Pavord, A.M. Tershakovec, M.M. Kitt, C. Assaid, J.A. Smith
Format: Article
Language:English
Published: Elsevier 2020-08-01
Series:World Allergy Organization Journal
Online Access:http://www.sciencedirect.com/science/article/pii/S193945512030106X

Internet

http://www.sciencedirect.com/science/article/pii/S193945512030106X

Similar Items